Rubio-Guerra AF,Vargas-Robles H, Suárez-Cuenca JA, Lozano-Nuevo JJ, Rodríguez-López L, Durán-Salgado MB, Escalante-Acosta BA

Language: Spanish
References: 11
Page: 146-151
PDF size: 520.94 Kb.

ABSTRACT

Background: Adipocytokines are adipocyte-secreted peptides that are involved in the pathways that lead to insulin resistance, inflammation and the development of cardiovascular disease.
Objective: To evaluate the levels of the adipocytokines resistin and adiponectin in normotensive and hypertensive diabetic patients.
Material and methods: Clinical and transversal study; circulating levels of resistin and adiponectin were measured by ELISA (RyDSystems Minneapolis) in 80 type-2 diabetic patients (40 normotensive and 40 hypertensive naïve to antihypertensive therapy), and in 40 normotensive non-diabetic subjects. Statistical analysis was performed with ANOVA.
Results: We found a non-significantly decreased levels of resistin in control group when compared with diabetic normotensive patients, (13.5 vs 16.7 ng/mL p › 0.05); however, the coexistence of hypertension increased significantly (25.9 ng/mL p‹ 0.005) those values. We also observed increased values of adiponectin in control group when compared with diabetic normotensive patients (9.6 vs 7.5 µg/mL, p‹0.05), but the coexistence of hypertension did not modified those values significantly (7.4 µg/dL p›0.05).
Conclusions: Diabetic patients have increased levels of resistin and lower values of adiponectin when compared with non diabetic subjects, coexistence of hypertension increase the levels of resistin but do not modified adiponectin values, this may explain why diabetic patients (hypertensive or not) had more complications than normotensive patients.

REFERENCES

1. Rubio-Guerra AF. Adipocitokinas. Regulación del equilibrio energético y de la resistencia a la insulina. En: Rubio AF. Síndrome metabólico. México: Nieto Editores, 2008;29- 35.

2. Falcão-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenço AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012 Apr 25. Doi:10.1111/j.1440- 1681.2011.05602.x

3. Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin Exp Pharmacol Physiol 2011;38:888-896.

4. Lozano-Nuevo JJ, Estrada-Garcia T, Vargas-Robles H, Escalante-Acosta BA, Rubio-Guerra AF. Correlation between circulating adhesion molecules and resistin levels in hypertensive type-2 diabetic patients. Inflamm Allergy Drug Targets 2011;10:27-31.

5. Rubio-Guerra AF, Cabrera-Miranda JL, Vargas-Robles H, Maceda-Serrano A, Lozano-Nuevo JJ, Escalante-Acosta BA. Correlation between Levels of circulating adipokines and adiponectin/resistin index with carotid intima-media thickness in hypertensive type 2 Diabetic Patients. Cardiology 2013;125:150-153.

6. Takata Y, Osawa H, Kurata M, Kurokawa M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008;51:534-539.

7. Schindler K, Vila G, Hoppichler F, Lechleitner M, et al. The impact of type 2 diabetes on circulating adipokines in patients with metabolic syndrome. Obes Facts 2012;5:270- 276.

8. Jee SH, Ahn CW, Park JS, Park CG, et al. Serum adiponectin and type 2 diabetes: a 6-year follow-up cohort study. Diabetes Metab J 2013;37:252-261.

9. Ellington AA, Malik AR, Klee GG, Turner ST, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007;50:708-714.

10. Rubio-Guerra AF, Vargas-Robles H, Lozano-Nuevo JJ, Elizalde-Barrera CI, et al. Beneficial effect of combination therapy with an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type-2 diabetes. Exp & Clin Cardiol 2012;17:202-204.

11. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 2009;157:415-426.